Existing biomarkers for ND are related to amyloid beta or tau proteins, which are involved in the pathophysiology of ND and are measured using neuroimaging techniques, such as brain magnetic resonance imaging, single-photon emission computed tomography or positron emission tomography, or cerebrospinal fluid testing [30,31]. Here, MAPT is linked to Norrie disease.